Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 46.00
Bid: 45.50
Ask: 46.50
Change: -0.50 (-1.08%)
Spread: 1.00 (2.198%)
Open: 46.50
High: 46.50
Low: 46.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 Aug 2020 09:30

RNS Number : 7832V
Avacta Group PLC
11 August 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Avacta Group plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

PREMIER MITON GROUP PLC

City and country of registered office (if applicable)

London, UK

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

06/08/2020

6. Date on which issuer notified (DD/MM/YYYY):

07/08/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

4.66%

N/A

4.66%

249,155,721

Position of previous notification (if

applicable)

8.13%

N/A

8.13%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BYYW9G87

11,609,794

4.66%

SUBTOTAL 8. A

11,609,794

4.66%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Premier Miton Group Plc

Premier Asset Management Midco Ltd

Premier Asset Management Holdings Ltd

Premier Asset Management Limited

Premier Investment Group Ltd

Premier Fund Managers Ltd

4.66%

4.66%

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

Please note that with effect from 27th April 2020 all investment management related activities for the Premier Miton Group plc will be carried out by Premier Fund Managers Limited. Miton Asset Management Limited and Miton Trust Managers Limited have ceased to carry out regulated activities.

 

Place of completion

LONDON, UK

Date of completion

07/08/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLMZGMRRMRGGZG
Date   Source Headline
8th Jan 20207:00 amRNSAvacta and Daewoong Establish Joint Venture
26th Nov 20199:00 amRNSHolding(s) in Company
22nd Nov 20198:41 amRNSDirector/PDMR Shareholding
13th Nov 20197:00 amRNSLG Chem Life Sciences Expands Partnership
11th Nov 20197:00 amRNSHolding(s) in Company
8th Nov 20196:30 pmRNSHolding(s) in Company
8th Nov 20196:26 pmRNSHolding(s) in Company
7th Nov 20191:00 pmRNSHolding(s) in Company
7th Nov 201911:00 amRNSHolding(s) in Company
6th Nov 20192:30 pmRNSHolding(s) in Company
4th Nov 20191:18 pmRNSResult of General Meeting
18th Oct 201912:06 pmRNSProposed Placing & Subscription to raise up to £9M
18th Oct 201912:05 pmRNSInterim Results for the Period Ended 31 July 2019
10th Oct 20197:00 amRNSCollaboration with ADC Therapeutics
5th Aug 20199:05 amRNSSecond Price Monitoring Extn
5th Aug 20199:00 amRNSPrice Monitoring Extension
29th Jul 20197:00 amRNSAvacta's CEO to Present at Biotech Investor Day
20th Jun 20197:00 amRNSAvacta and Selexis Partner to Develop Cell Line
19th Jun 20197:00 amRNSTurner Pope Investor Evening
12th Jun 20197:00 amRNSAvacta's CSO to Present at Major US Conference
10th Jun 20197:00 amRNSAvacta hits Clinical Candidate Selection Milestone
3rd Jun 20197:00 amRNSTMAC Programme Accelerates
23rd Apr 20193:48 pmRNSIssue of Equity
12th Apr 20192:46 pmRNSHolding(s) in Company
9th Apr 20197:00 amRNSInterim Results
8th Mar 201912:14 pmRNSIssue of Equity
6th Feb 201912:27 pmEQSHardman & Co Research: Avacta (AVCT): A second wake-up call for the market
4th Feb 20197:00 amRNSModerna Exercises Exclusive Product License Option
28th Jan 20197:00 amRNSDirector Appointment
21st Jan 20193:40 pmRNSResult of Annual General Meeting
21st Jan 20197:00 amRNSAGM Business Update and Notice of Results
18th Jan 20195:08 pmRNSShare Incentive Plan/Issue of Equity
9th Jan 201911:06 amRNSHolding(s) in Company
7th Jan 20192:50 pmRNSDirector/PDMR Shareholdings
3rd Jan 20198:56 amRNSHolding(s) in Company
2nd Jan 20197:00 amRNSDirector/PDMR Shareholding
21st Dec 20181:41 pmRNSHolding(s) in Company
19th Dec 20183:32 pmRNSHolding(s) in Company
17th Dec 20187:00 amRNSAvacta London Science Day
12th Dec 201812:50 pmRNSHolding(s) in Company
12th Dec 201812:44 pmRNSHolding(s) in Company
12th Dec 20187:00 amRNSAppointment of Chief Medical Officer
11th Dec 20187:00 amRNSPosting of Annual Report and Notice of AGM
10th Dec 20182:05 pmRNSSecond Price Monitoring Extn
10th Dec 20182:00 pmRNSPrice Monitoring Extension
10th Dec 20187:30 amEQSHardman & Co Research: Avacta (AVCT): Wake-up call for the market
10th Dec 20187:00 amRNSDevelopment Partnership with LG Chem Life Sciences
12th Nov 20187:00 amRNSAvacta to Present at Major European Conference
11th Oct 20187:00 amRNSAvacta's CTO to Present at Major US Conference
10th Oct 20187:00 amRNSAvacta agrees Affimer reagent licensing deal

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.